Endocardial Solutions Reports Second Quarter Earnings Results: Sales Up 49%, North American EnSite Catheter Revenues Up 91% Over Q2'00

July 18, 2001
MINNEAPOLIS / ST.PAUL -- Endocardial Solutions, Inc. (Nasdaq: ECSI) today reported net sales for the second quarter 2001 of $5,577,704, compared with $3,737,131 for the same period of 2000, an increase of 49%. The net loss for the second quarter ended June 30, 2001, is $2,462,479, or $.17 per share, compared with a net loss of $3,137,461, or $.31 per share, for the same period of 2000. Year-to-date sales are $10,179,870, compared to $7,097,189 for the same period last year, reflecting an increase of 43%. North American catheter sales are 102% over the same period.

"Virtually every financial indicator was at record quarterly levels," said Jim Bullock, President and Chief Executive Officer. "We look forward to sharing these results with you in greater detail during our conference call tomorrow at 9:30am CST," said Bullock.

"Also during the conference call we will provide an update on the progress of our next generation software, as well as discuss the Company's evolving strategy to strengthen our presence in the European market," stated Bullock.

<*dv_2*>"This is a very exciting time for our Company!" concluded Bullock.

Second Quarter 2001 Earnings Conference Call

July 19, 2001

9:30am (CST)

1-877-272-5391

Moderator: Jim Bullock

Instant Replay through July 26, 2001

1-800-642-1687

Conference ID: 1180956

The U.S. Food and Drug Administration cleared the EnSite 3000

Based in St. Paul, Minnesota, Endocardial Solutions (www.endocardial.com) develops, manufactures and markets technology for diagnostic mapping of complex arrhythmias (abnormally rapid heartbeats caused by irregular electrical activity in the heart). The EnSite 3000

The discussion above is based on preliminary financial results, which are subject to further review and adjustment, and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding gross margins, operating expenses and revenue expectations, that involve a number of risks and uncertainties. A number of factors should be considered in conjunction with these forward-looking statements. These factors are set forth in the cautionary statements included in Exhibit 99 to Endocardial Solutions’ Form 10-K/A for the year ended December 31, 2000, filed with the Securities and Exchange Commission. Endocardial Solutions cautions investors and others to review the statements set forth in that report and that other factors may prove to be important in affecting the business and results of operations of Endocardial Solutions.

Contacts:

Jim Bullock, President and CEO, Endocardial Solutions (651) 523-6928 jbullock@endocardial.com